Literature DB >> 30210852

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.

Hassan Mirza1, Duncan Harding2, Naser Al-Balushi3.   

Abstract

Schizophrenia is a serious long-term mental disorder which usually presents in adolescence or early adulthood. However, poor adherence to oral antipsychotics can lead to relapse and rehospitalisation. We report an adolescent male with schizophrenia who was referred to the South London & Maudsley National Health Service Foundation Trust, London, UK, in 2015 due to worsening psychotic symptoms. Following poor compliance with oral medications, a four-week regimen of paliperidone palmitate long-acting injections was initiated, with an initial positive response. However, 10 days after the second dose, the patient developed severe acute-onset delirium with fluctuating levels of consciousness. Paliperidone palmitate was discontinued and the patient instead underwent a course of zuclopenthixol decanoate long-acting injections with a favourable outcome.

Entities:  

Keywords:  Adolescent Psychiatry; Antipsychotic Agents; Case Report; Delirium; Paliperidone Palmitate; Schizophrenia; United Kingdom; Zuclopenthixol

Mesh:

Substances:

Year:  2018        PMID: 30210852      PMCID: PMC6132512          DOI: 10.18295/squmj.2018.18.02.014

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  12 in total

1.  Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.

Authors:  Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2011-01       Impact factor: 4.384

Review 2.  Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

Authors:  Jon McClellan; Saundra Stock
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-09       Impact factor: 8.829

3.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

Review 4.  Long-Acting Injectable Antipsychotics in Children and Adolescents.

Authors:  Sarah Lytle; Molly McVoy; Martha Sajatovic
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-01-23       Impact factor: 2.576

Review 5.  Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis.

Authors:  Nicolas A Crossley; Miguel Constante; Philip McGuire; Paddy Power
Journal:  Br J Psychiatry       Date:  2010-06       Impact factor: 9.319

6.  Efficacy of Long-Acting Injectable Antipsychotics in Adolescents.

Authors:  Stephanie Pope; Solomon G Zaraa
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-03-30       Impact factor: 2.576

7.  Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.

Authors:  Anja Kokalj; Nikolina Rijavec; Rok Tavčar
Journal:  BMJ Case Rep       Date:  2016-06-22

Review 8.  Two cases of long-acting paliperidone in adolescence.

Authors:  Marina Fàbrega; Gisela Sugranyes; Inmaculada Baeza
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

9.  Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.

Authors:  Larry Alphs; Srihari Gopal; Keith Karcher; Justine Kent; Jennifer Kern Sliwa; Stuart Kushner; Isaac Nuamah; Jaskaran Singh
Journal:  Curr Drug Saf       Date:  2011-02-01

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.